Wendell Wierenga's Stock Option Exercise and Sale Plan

Wendell Wierenga, a director at Cytokinetics, Incorporated, has filed a Form 144 with the SEC detailing his plan to sell 4,375 shares of common stock acquired through the exercise of stock options. The shares were acquired on October 27, 2025, and the sale is planned for the same date. The aggregate market value of the shares to be sold is approximately $253,006.25. The transaction will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing indicates that there have been no other sales of securities by Wierenga in the past three months.